Proteins & Peptides

Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.351, also known as variant Beta originally discovered in South Africa, and contains the nine known mutations listed below, in addition to deletion 242-244. It also contains mutations 682RRAR685>A, K986P and V987P. The construct has a C-terminal His-tag (6xHis). Note that the expected MW of the S1+S2 monomer is 137kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein was affinity purified.<br /><br />*Deletion 242-244 is known as 241-243 in some databases and on the CDC website. This is the same deletion. As stated by Tegally et al., Nature 2021: "We also observe a deletion of three amino acids at positions 242 to 244, which was seen in samples extracted and generated in different laboratories across the NGS-SA. This region is difficult to align; the deletion could potentially

Anti-CD235a antibody is a purified biotinylated recombinant human antibody which recognizes the CD235a/GYPA protein. This antibody has been tested for specific binding to purified human CD235a protein (BPS Bioscience #101196) in a colorimetric ELISA binding assay. This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%.

Recombinant SARS-CoV-2 Spike protein S1 subunit, encompassing amino acids 16-685. This protein corresponds to SARS-CoV2 variant B.1.429, also known as variant Epsilon originally discovered in California (USA), and contains mutations W152C, L452R and D614G. The construct also contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. 

Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617 originally discovered in India, and contains mutations L452R, E484Q, D614G and P681R. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified.  

Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.618, originally identified in India, and contains deletion 145/146YH as well as mutations E484K and D614G.  The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified.

Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.2, also known as variant Delta, originally discovered in India. It contains the eight Delta variant mutations indicated below in addition to deletion 156/157. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified. 

Recombinant human IL2R γ (Interleukin-2 receptor subunit gamma), encompassing amino acids 23-262. This construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified.

Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.618 originally identified in India, and contains mutation E484K. The construct contains a C-terminal Avi-Tag™ followed by a His-tag (6xHis). The protein was affinity purified. 

Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.2.1 also known as variant Delta Plus originally identified in India, and contains mutations T19R, G142D, R158G, K417N, L452R, T478K, D614G, P681R and D950N as well as deletion E156-F157.  The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified.